Joshua Richter - Associate Professor, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA. What ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Investing.com -- Syndax Pharmaceuticals Inc (NASDAQ: SNDX) stock gained 2.5% after the FDA granted Priority Review for its supplemental New Drug Application (sNDA) for Revuforj, potentially expanding ...

With the summer humidity plopped right over Central New York, catching a flick in a nice air-conditioned theater may not sound too bad. This week, Bridge Street’s Brian ...

CAR-T cells, which are genetically programmed to specifically recognize and kill target cells, have altered the therapeutic landscape of lymphoma. After the tumor antigens are identified by scFv, ...

The "Hematology Collaboration and Licensing Deals 2016-2025" has been added to ResearchAndMarkets.com's offering.Fully revised and updated, the report provides details of 192 hematology deals from ...

Nicole Verdun, MD, super office director of the FDA’s Office of Therapeutic Products (OTP) and her deputy Rachael Anatol, PhD ...

New vegans often worry about certain nutrients. Dietitians explain why each matters and share practical fixes, from fortified ...

Autosomal dominant tubulointerstitial kidney disease, better known as ADTKD, is a group of kidney disorders which are inherited. Sheri and David Dafoe have first-hand knowledge ...

On Tuesday, the U.S. Food and Drug Administration announced a new initiative to offer expedited reviews for new medicines, an ...

Median OS improved from 12.5 months with rituximab (Rituxan), gemcitabine, and oxaliplatin (R-GemOx) to 19.5 months with the addition of polatuzumab vedotin (Pola-R-GemOx; HR 0.60, 95% CI 0.43-0.83, ...